Exelixis (EXEL) is a publicly traded Healthcare sector company. As of August 19, 2026, EXEL trades at $52.98 with a market cap of $12.96B and a P/E ratio of 29.43. EXEL moved -0.26% today. Year to date, EXEL is +21.20%; over the trailing twelve months it is +40.68%. Its 52-week range spans $31.90 to $57.57. Analyst consensus is neutral with an average price target of $51.75. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for EXEL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $52.98 |
| Market Cap | $12.96B |
| P/E Ratio | 29.43 |
| EPS | $1.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $57.57 |
| 52-Week Low | $31.90 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.17B |
| Net Income | $521.27M |
| Gross Margin | 96.49% |
14 analysts cover EXEL: 0 strong buy, 4 buy, 9 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $51.75.